<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143323</url>
  </required_header>
  <id_info>
    <org_study_id>DILI_Healthy</org_study_id>
    <nct_id>NCT02143323</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)</brief_title>
  <official_title>A Clinical Study to Evaluate the Effect of Glutathion S-transferase Polymorphism on Pharmacokinetics/Pharmacodynamics After Multiple Administration of Amoxicillin/Clavulanate and Explore Biomarkers for Drug-induced Liver Injury (DILI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has an open-label, one-sequence, multiple drug administration design. The purpose
      of this study is as follows;

        -  To evaluate the change of liver function according to glutathione s-transferase (GST)
           genotype after the multiple administration of amoxicillin/clavulanate.

        -  To evaluate the intrinsic metabolite, human leukocyte antigen (HLA) genotype, and
           microRNA (miRNA) based on liver function change as the candidate biomarker for DILI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>22 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>22 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase (ALP)</measure>
    <time_frame>22 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSTT1/GSTM1 wild/null type</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSTT1/GSTM1 null/wild type</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSTT1/GSTM1 null/null type</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmentin tablet</intervention_name>
    <arm_group_label>Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild</arm_group_label>
    <arm_group_label>GSTT1/GSTM1 wild/null type</arm_group_label>
    <arm_group_label>GSTT1/GSTM1 null/wild type</arm_group_label>
    <arm_group_label>GSTT1/GSTM1 null/null type</arm_group_label>
    <other_name>Experimental: Augmentin</other_name>
    <other_name>Augmentin 3 tablets (Amoxicilin:clavualanate=2:1) bid, for 14days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject with sufficient ability to understand the nature of the study and any hazards
             of participating in it. Provide written informed consent after being fully informed
             about the study procedures

          2. Healthy male of female subjects aged 20 - 45 years

          3. Subjects whose body mass index (BMI) in the range 18.5 kg/m2 (inclusive) - 27 kg/m2
             (exclusive)

        Exclusion Criteria:

          1. Subject with clinically significant disease in liver, kidney, nerve system,
             respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular
             system, mental disease or with medical history

          2. Subject who has taken any prescribed drugs, herbal agents or crude drugs within 2
             weeks before study drug administration

          3. Subject who did blood donation during 1 months before the study or Blood donation
             during 2 months before the study

          4. Subject with presence or history of severe adverse reaction to study drug

          5. Subject who cannot prevent pregnancy during the study period.

          6. Female subject who are pregnant.

          7. Subject who drank over 21 units/week of alcohol or subjects who would not be able to
             stop drinking alcohol during the hospitalization

          8. Subject who are Heavy smoker more than 10 cigarettes/day within 3 months prior to
             screening or subjects who would not be able to stop smoking during the
             hospitalization.

          9. Subject judged not eligible for study participation by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jieon Lee</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>In-Jin Jang, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>GST, DILI, biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

